mAbxience is a Spanish-based biopharmaceutical company specializing in the development, production, and commercialization of biosimilars and contract development and manufacturing organization (CDMO) services. Founded in 2010, the company focuses on providing accessible and affordable biological medicines globally. mAbxience's product portfolio includes biosimilar versions of infusion-based cancer drugs such as Avastin (bevacizumab) and Rituxan (rituximab). The company operates three multi-product facilities in Europe and South America, which have obtained Good Manufacturing Practices (GMP) approval from regulatory bodies including the FDA and EMA. In August 2022, Fresenius Kabi acquired a majority stake in mAbxience for 495 million euros, with Insud Pharma retaining partial ownership.
mAbxience's manufacturing capabilities include a 4,000 L single-use bioreactor at its Genhelix site in Spain, making it the largest single biologics manufacturing facility in the country and the first in Europe with fully integrated single-use technology. The company's expertise spans cell development, process optimization, analytical methods, and manufacturing. mAbxience has demonstrated its capabilities through strategic partnerships, such as its collaboration with AstraZeneca on the Covid-19 vaccine project. The company has also been appointed to lead a World Health Organization (WHO) project aimed at developing the next generation of mRNA therapeutics.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.